PSA Screening: Why It's One of the Most Controversial Decisions in Preventive Medicine

PSA (prostate-specific antigen) is one of the most commonly ordered blood tests in men over 50. We cover the mechanism and basic reference ranges for this test in more detail in our entry on PSA and prostate health — here, we focus on a different, separate question that has divided urologists, oncologists, and guideline-writers for decades: should asymptomatic men be routinely screened for prostate cancer using PSA, or not?

This question doesn't have one obvious answer, and how much the official answer from the US Preventive Services Task Force (USPSTF) has changed over the past fifteen-plus years is itself a good indicator of just how difficult this topic is. Understanding the source of this controversy — not the biology of PSA itself, but the balance of benefits and harms from screening an entire population of asymptomatic men — is key to having an informed conversation with your doctor about whether and when testing makes sense.

The USPSTF grades preventive recommendations on a letter scale, where A and B mean a recommendation for routine testing, C means an individual decision after discussion with a doctor, and D means a recommendation against routine testing. In 2012, the agency rated PSA screening for all men, regardless of age, as D — a recommendation against routine screening.

Six years later, following further analysis of data from the large randomized trials described in the next section, as well as criticism that the 2012 D recommendation didn't fully account for the benefit of screening in younger men, the USPSTF revised its position.

The source of the biggest controversy is the results of two large, randomized screening trials published almost simultaneously in 2009 in the New England Journal of Medicine — one American, one European — that reached partly different conclusions.

At the core of the controversy is a biological feature of prostate cancer itself, not a flaw in the PSA test as such. Prostate cancer is a tumor with an unusually variable clinical course — from aggressive forms that can be life-threatening within a few years, to such slow-growing (indolent) forms that many men die of unrelated causes before the tumor ever produces any symptoms at all. Autopsy studies have long shown that microscopic foci of prostate cancer are present in a substantial proportion of older men who never had, and never would have had, any symptoms related to this cancer.

The problem is that neither the PSA test nor even a biopsy can reliably distinguish, at the time of diagnosis, which specific cancer is the aggressive form requiring treatment and which is the indolent form that would be safer left alone. As a result, an elevated PSA leads to a biopsy, and detecting cancer on biopsy — even a low-grade one — has historically often led to treatment (prostatectomy or radiation therapy), even though some of these cancers would never have threatened the patient's life.

The second element of the problem is real, not merely theoretical, harm from the diagnostic workup and treatment itself. Prostate biopsy carries a risk of bleeding, infection, and, rarely, complications requiring hospitalization. Radical treatment (prostatectomy, radiation therapy) carries a substantial risk of urinary incontinence and erectile dysfunction, which can be permanent. For a man whose cancer would never have progressed into symptomatic disease, these complications are a pure cost with no corresponding benefit — and that's exactly the core of what overtreatment means.

This doesn't mean PSA screening has no value — it means its value depends on an individual balance of benefits and harms that differs between patients depending on age, life expectancy, family history, and personal priorities about how a given person weighs the risk of treatment complications against the risk of missing an aggressive cancer.

Even though the final decision is always individual, data from both large trials and the USPSTF recommendation allow a general picture to emerge. PSA screening is most often considered a reasonable option for men aged 55–69 without significant life-expectancy-limiting illness, especially with a family history of prostate cancer or membership in a group with documented higher risk for this cancer.

Screening is, conversely, discouraged — per the USPSTF's D recommendation — for men aged 70 and older, where life expectancy and the typically slow course of most prostate cancers mean the potential harms from overdiagnosis and overtreatment outweigh the small, if any, benefit in extending life. This age-based distinction is one of the most important, concrete takeaways from this whole controversy — a patient's age and overall health status matter more for the screening decision than the mere availability of the test.

The controversy around PSA screening doesn't exist because the test is "bad" or because doctors don't know what to do — it exists because of a genuine, hard-to-resolve biological ambiguity in prostate cancer as a disease with a highly variable course. It's one of the best examples in preventive medicine of why the answer to "should I get tested" doesn't have to be, and in this case shouldn't be, a single universal yes or no — it can, and should, depend on an individual patient's circumstances and values.